A meta-analysis of single HCV-untreated arm of studies evaluating outcomes after curative treatments of HCV-related hepatocellular carcinoma
| Title: | A meta-analysis of single HCV-untreated arm of studies evaluating outcomes after curative treatments of HCV-related hepatocellular carcinoma |
|---|---|
| Authors: | Cabibbo G.; Petta S.; Barbara M.; Missale G.; Virdone R.; Caturelli E.; Piscaglia F.; Morisco F.; Colecchia A.; Farinati F.; Giannini E.; Trevisani F.; Craxi A.; Colombo M.; Camma C.; Bucci L.; Zoli M.; Garuti F.; Lenzi B.; Biselli M.; Caraceni P.; Cucchetti A.; Gramenzi A.; Granito A.; Magalotti D.; Serra C.; Negrini G.; Napoli L.; Salvatore V.; Benevento F.; Benvegnu L.; Gazzola A.; Murer F.; Pozzan C.; Vanin V.; Moscatelli A.; Pellegatta G.; Picciotto A.; Savarino V.; Ciccarese F.; Del Poggio P.; Olmi S.; de Matthaeis N.; Balsamo M. D. M. C.; Vavassori E.; Roselli P.; Dell'Isola S.; Ialungo A. M.; Rastrelli E.; Attardo S.; Rossi M.; Costantino A.; Affronti A.; Affronti M.; Mascari M.; Felder M.; Mega A.; Gasbarrini A.; Pompili M.; Rinninella E.; Sacco R.; Mismas V.; Foschi F. G.; Dall'Aglio A. C.; Feletti V.; Lanzi A.; Cappa F. M.; Neri E.; Stefanini G. F.; Tamberi S.; Olivani A.; Biasini E.; Nardone G.; Guarino M.; Svegliati-Baroni G.; Ortolani A.; Masotto A.; Marchetti F.; Valerio M.; Marra F.; Aburas S.; Inghilesi A. L.; Cappelli A.; Golfieri R.; Mosconi C.; Renzulli M.; Coccoli P.; Zamparelli M. S. |
| Contributors: | Cabibbo, G.; Petta, S.; Barbara, M.; Missale, G.; Virdone, R.; Caturelli, E.; Piscaglia, F.; Morisco, F.; Colecchia, A.; Farinati, F.; Giannini, E.; Trevisani, F.; Craxi, A.; Colombo, M.; Camma, C.; Bucci, L.; Zoli, M.; Garuti, F.; Lenzi, B.; Biselli, M.; Caraceni, P.; Cucchetti, A.; Gramenzi, A.; Granito, A.; Magalotti, D.; Serra, C.; Negrini, G.; Napoli, L.; Salvatore, V.; Benevento, F.; Benvegnu, L.; Gazzola, A.; Murer, F.; Pozzan, C.; Vanin, V.; Moscatelli, A.; Pellegatta, G.; Picciotto, A.; Savarino, V.; Ciccarese, F.; Del Poggio, P.; Olmi, S.; de Matthaeis, N.; Balsamo, M. D. M. C.; Vavassori, E.; Roselli, P.; Dell'Isola, S.; Ialungo, A. M.; Rastrelli, E.; Attardo, S.; Rossi, M.; Costantino, A.; Affronti, A.; Affronti, M.; Mascari, M.; Felder, M.; Mega, A.; Gasbarrini, A.; Pompili, M.; Rinninella, E.; Sacco, R.; Mismas, V.; Foschi, F. G.; Dall'Aglio, A. C.; Feletti, V.; Lanzi, A.; Cappa, F. M.; Neri, E.; Stefanini, G. F.; Tamberi, S.; Olivani, A.; Biasini, E.; Nardone, G.; Guarino, M.; Svegliati-Baroni, G.; Ortolani, A.; Masotto, A.; Marchetti, F.; Valerio, M.; Marra, F.; Aburas, S.; Inghilesi, A. L.; Cappelli, A.; Golfieri, R.; Mosconi, C.; Renzulli, M.; Coccoli, P.; Zamparelli, M. S. |
| Publisher Information: | Blackwell Publishing Ltd |
| Publication Year: | 2017 |
| Subject Terms: | hepatocellular carcinoma; prognosis; recurrences; survival; Carcinoma; Hepatocellular; Hepatitis C; Humans; Liver Neoplasms; Neoplasm Recurrence; Local |
| Description: | Background & Aims: Determining risk for recurrence or survival after curative resection or ablation in patients with hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC) is important for stratifying patients according to expected outcomes in future studies of adjuvant therapy in the era of direct-acting antivirals (DAAs). The aims of this meta-analysis were to estimate the recurrence and survival probabilities of HCV-related early HCC following complete response after potentially curative treatment and to identify predictors of recurrence and survival. Methods: Studies reporting time-dependent outcomes (HCC recurrence or death) after potentially curative treatment of HCV-related early HCC were identified in MEDLINE through May 2016. Data on patient populations and outcomes were extracted from each study by three independent observers and combined using a distribution-free summary survival curve. Primary outcomes were actuarial probabilities of recurrence and survival. Results: Eleven studies met the inclusion criteria. Pooled estimates of actuarial recurrence rates were 7.4% at 6months and 47.0% at 2years. Pooled estimates of actuarial survival rates were 79.8% at 3years and 58.6% at 5years. Heterogeneity among studies was highly significant for all outcomes. By univariate meta-regression analyses, lower serum albumin, randomized controlled trial study design and follow-up were independently associated with higher recurrence risk, whereas tumour size and alpha-foetoprotein levels were associated with higher mortality. Conclusions: This meta-analysis showed that recurrence risk and survival are extremely variable in patients with successfully treated HCV-related HCC, providing a useful benchmark for indirect comparisons of the benefits of DAAs and for a correct design of randomized controlled trials in the adjuvant setting. |
| Document Type: | article in journal/newspaper |
| Language: | English |
| Relation: | info:eu-repo/semantics/altIdentifier/wos/WOS:000405575400010; volume:37; issue:8; firstpage:1157; lastpage:1166; numberofpages:10; journal:LIVER INTERNATIONAL; https://hdl.handle.net/20.500.11768/125295 |
| DOI: | 10.1111/liv.13357 |
| Availability: | https://hdl.handle.net/20.500.11768/125295; https://doi.org/10.1111/liv.13357 |
| Accession Number: | edsbas.D49824CB |
| Database: | BASE |